Related references
Note: Only part of the references are listed.A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma
Lisa Greene et al.
MOLECULAR CANCER RESEARCH (2019)
Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
Meredith Pelster et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma
Dominic Lapadula et al.
MOLECULAR CANCER RESEARCH (2019)
The Cancer Genome Atlas: Creating Lasting Value beyond Its Data
Carolyn Hutter et al.
CELL (2018)
Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973-2013)
Mary E. Aronow et al.
OCULAR ONCOLOGY AND PATHOLOGY (2018)
Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma
Vishal Jindal
CHINESE CLINICAL ONCOLOGY (2018)
Treatment of uveal melanoma: where are we now?
Jessica Yang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma
Asad Javed et al.
IMMUNOTHERAPY (2017)
Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma
Hanyin Cheng et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
A. Gordon Robertson et al.
CANCER CELL (2017)
Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects
Abdulla A-B Badawy
INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH (2017)
Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies
Alain P. Algazi et al.
CANCER (2016)
A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer
Nicholas C. D'Amato et al.
CANCER RESEARCH (2015)
Uveal melanoma: Estimating prognosis
Swathi Kaliki et al.
INDIAN JOURNAL OF OPHTHALMOLOGY (2015)
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein et al.
NATURE GENETICS (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Michael Platten et al.
CANCER RESEARCH (2012)
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Luc Pilotte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Christiane A. Opitz et al.
NATURE (2011)
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
J. William Harbour et al.
SCIENCE (2010)
Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice
Masaaki Kanai et al.
MOLECULAR BRAIN (2009)
Incidence of uveal melanoma in Europe
Gianni Virgili et al.
OPHTHALMOLOGY (2007)
Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division
GK Lee et al.
IMMUNOLOGY (2002)
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase
G Frumento et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Share Paper
